Literature DB >> 8276836

The human alpha 2 integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression.

M M Zutter1, S A Santoro, A S Painter, Y L Tsung, A Gafford.   

Abstract

The alpha 2 beta 1 serves as a collagen receptor or a collagen/laminin receptor, depending upon cell type. Expression of the integrin is regulated during normal cellular differentiation and is altered during carcinogenesis. We have previously demonstrated that increased expression of the alpha 2 beta 1 integrin during megakaryocytic differentiation is a consequence of increased alpha 2 mRNA due to transcriptional activation of the alpha 2 integrin gene and that the decreased expression of the integrin in breast adenocarcinoma is due to decreased steady-state levels of alpha 2 mRNA. We now report the identification and characterization of the 5'-flanking region of the alpha 2 integrin gene. The 5'-untranslated region of the alpha 2 mRNA extends 129 base pairs 5' to the site of translation initiation. The promoter region lacks TATA and CAAT boxes but contains an abbreviated initiator sequence and six Sp1 binding sites. Consensus binding sites for AP-1 and AP-2 complexes, a GATA box, a Pu.1 box, and two palindromic motifs with potential to bind the estrogen receptor are also present. A 961-base pair fragment of the 5'-flanking region directs both cell type- and differentiation-specific expression of a reporter gene in T47-D epithelial cells and in pluripotent hematopoietic K562 cells upon megakaryocytic differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276836

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts.

Authors:  Iya Znoyko; Maria Trojanowska; Adrian Reuben
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

3.  Regulation of keratin and integrin gene expression in cancer and drug resistance.

Authors:  N Daly; P Meleady; D Walsh; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.

Authors:  Xiaocai Yan; Bryon D Johnson; Rimas J Orentas
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103).

Authors:  P W Robinson; S J Green; C Carter; J Coadwell; P J Kilshaw
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

6.  N-myc over-expression downregulates alpha3beta1 integrin expression in human Saos-2 osteosarcoma cells.

Authors:  R Judware; L A Culp
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

7.  C-reactive protein binds to integrin α2 and Fcγ receptor I, leading to breast cell adhesion and breast cancer progression.

Authors:  E-S Kim; S Y Kim; M Koh; H-M Lee; K Kim; J Jung; H S Kim; W K Moon; S Hwang; A Moon
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

Review 8.  Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation.

Authors:  K Sobue; K Hayashi; W Nishida
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

Review 9.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

10.  Enhanced binding of poly(ADP-ribose)polymerase-1 and Ku80/70 to the ITGA2 promoter via an extended cytosine-adenosine repeat.

Authors:  Yann Cheli; Shirley A Williams; Robert Ballotti; Diane J Nugent; Thomas J Kunicki
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.